Abstract:Abstract Background The bifunctional methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase (MTHFD2) has been reported to play an oncogenic role in various types of cancers. However, the function of MTHFD2 in urothelial carcinomas of bladder (UCB) and its association with tumor immune infiltration remains unknown. We aim to examine the suitability of MTHFD2 to be a novel biomarker of bladder cancer and whether MTHFD2 is linked to immune infiltration. Methods RNA sequencing data and clinical information (bladder cancer samples: normal samples = 414: 19) were downloaded from The Cancer Genome Atlas official website. Western blot analysis was performed to detect MTHFD2 expression in human bladder cancer (BLCA) cells and normal urothelial cell line SV-HUC-1. Associations between MTHFD2 expression and clinicopathological features were analyzed using Mann Whitney U test or Kruskal-Wallis H test. The “survival” and “survminer” packages were utilized to plot Kaplan-Meier survival curves. Moreover, the gene set enrichment analysis (GSEA) was conducted using a clusterProfiler package. The correlation of MTHFD2 expression with immune infiltration level was estimated using the single sample GSEA (ssGSEA) algorithm. Furthermore, associations between MTHFD2 and immune checkpoint genes were evaluated using the correlation analysis. Results Transcriptome analysis manifested that MTHFD2 was highly expressed in UCB tissues than normal bladder tissues, which was further confirmed by western blot analysis in human BLCA cells and SV-HUC-1 cells. Moreover, MTHFD2 high expression was significantly associated with the advanced disease progression. Also, the high expression of MTHFD2 was correlated with poor prognosis, and MTHFD2 was considered as an independent prognostic factor for disease specific survival. Furthermore, a number of cancer-related pathways were enriched in MTHFD2 high group, including NF-κB activation, JAK/STAT, and cancer immunotherapy by PD1 blockade. Several immune checkpoint molecules were also strongly associated with MTHFD2 expression, including PDCD1, CD274, CTLA4, CD276, LAG3, HAVCR2, and TIGIT. Conclusions MTHFD2 expression was remarkably elevated in UCB, suggesting that MTHFD2 could be a promising biomarker for BLCA as well as novel target for anti-cancer immunotherapy since its close association with immune infiltration.

DACH2 as an independent biomarker for prediction of prognosis in muscle-invasive bladder urothelial carcinoma

Prospective Validation of DACH2 As a Novel Biomarker for Prediction of Metastasis and Prognosis in Muscle-Invasive Urothelial Carcinoma of the Bladder

Expression of dachshund homolog 2 gene in human bladder urothelial cancer and its clinical significance

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer.

Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups

Prognostic Significance of Murine Double Minute 2 Expression in Tumor Cells in Upper Tract Urothelial Carcinoma: An Analysis of 341 Cases in a Large Chinese Center.

Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer

Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer

MTHFD2 is a Potential Oncogene for Its Strong Association with Poor Prognosis and High Level of Immune Infiltrates in Urothelial Carcinomas of Bladder.

Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor

Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival.

Upregulation of Arp2 Expression is Associated with the Prognosis and Prediction of Lymph Node Metastasis in Bladder Urothelial Carcinoma

Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma

The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer

Clinical Significance of the Reduction of UT-B Expression in Urothelial Carcinoma of the Bladder

Correlationship between expression of Paxillin in bladder urothelial carcinoma and lymph node metastasis and survival prognosis

Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Transcriptomic Profiling Identifies DCBLD2 As a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.